Tevogen Bio (NASDAQ:TVGN) Stock Price Down 10.7% – Should You Sell?

Tevogen Bio Holdings Inc. (NASDAQ:TVGN) shares traded down 10.7% on Thursday. The company traded as low as $5.29 and last traded at $5.11. Approximately 3,890 shares were traded during mid-day trading, a decline of 61% from the average daily volume of 9,976 shares. The stock had previously closed at $5.72.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tevogen Bio in a research report on Thursday, October 15th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Tevogen Bio currently has an average rating of “Reduce” and an average target price of $100.00.

Tevogen Bio Stock Down 10.7%

The stock has a market cap of $33.27 million, a P/E ratio of -1.10 and a beta of 0.21. The business has a 50-day simple moving average of $6.90 and a 200-day simple moving average of $8.07.

Tevogen Bio (NASDAQ:TVGN) last released its earnings results on Friday, August 14th. The company reported ($1.52) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.53) by $1.01.

Tevogen Bio Company Profile

Tevogen Bio is a clinical-stage biotechnology company focused on developing off-the-shelf T-cell therapies for patients with viral infections, cancer and other serious medical conditions. Its approach is designed to use virus-specific cytotoxic T lymphocytes to target diseased cells while limiting the challenges associated with individualized cell therapies.

The company’s lead program, TVGN 489, is an investigational T-cell therapy intended to address COVID-19 and other conditions caused by SARS-CoV-2, particularly among immunocompromised patients.